Verve Therapeutics, Inc. Contracts & Agreements
41 Contracts & Agreements
- Business Finance (7 contracts)
- Business Operations (3)
- Human Resources (19)
- Intellectual Property (3)
- Real Estate (4)
- Uncategorized (5)
- Advisor Agreement, dated May 30, 2024, by and between the Registrant and Andrew Bellinger (Filed With SEC on August 8, 2024)
- Separation Agreement, dated May 30, 2024, by and between the Registrant and Andrew Bellinger (Filed With SEC on August 8, 2024)
- Stock Purchase Agreement, dated as of November 28, 2023, by and between the Registrant and Eli Lilly and Company (Filed With SEC on February 27, 2024)
- Employment Agreement, dated as of June 11, 2021, between the Registrant and Andrew Bellinger, M.D., Ph.D., as amended (Filed With SEC on February 27, 2024)
- License Agreement, dated October 4, 2021, by and between the Registrant and Novartis Pharma AG, as amended (Filed With SEC on February 27, 2024)
- Summary of Non-Employee Director Compensation Program (Filed With SEC on February 27, 2024)
- Form of Nonstatutory Stock Option Agreement under 2024 Inducement Stock Incentive Plan (Filed With SEC on February 27, 2024)
- Form of Restricted Stock Unit Agreement under 2024 Inducement Stock Incentive Plan (Filed With SEC on February 27, 2024)
- 2024 Inducement Stock Incentive Plan (Filed With SEC on February 27, 2024)
- Underwriting Agreement, dated November 28, 2023, by and among the Company and Jefferies LLC, Guggenheim Securities, LLC, William Blair & Company, L.L.C., BMO Capital Markets Corp.... (Filed With SEC on November 29, 2023)
- Second Amendment to Lease, dated as of June 17, 2022, by and between the Registrant and ARE-MA Region No. 87 Tenant, LLC (Filed With SEC on August 9, 2022)
- Underwriting Agreement, dated July 20, 2022, by and among the Company and J.P. Morgan Securities LLC, Jefferies LLC, Guggenheim Securities, LLC and William Blair & Company, L.L.C (Filed With SEC on July 21, 2022)
- Employment Agreement, dated as of November 26, 2021, between the Registrant and Allison Dorval (Filed With SEC on March 14, 2022)
- First Amendment to Lease, dated as of January 4, 2022, by and between the Registrant and ARE-MA Region No. 87 Tenant, LLC (Filed With SEC on March 14, 2022)
- Summary of Non-Employee Director Compensation Program (Filed With SEC on March 14, 2022)
- Form of Restricted Stock Unit Agreement under the 2021 Stock Incentive Plan (Filed With SEC on March 14, 2022)
- Form of Stock Option Agreement under the 2021 Stock Incentive Plan (Filed With SEC on March 14, 2022)
- Description of Securities Registered under Section 12 of the Exchange Act (Filed With SEC on March 14, 2022)
- Lease by and between Verve Therapeutics, Inc. and ARE-MA Region No. 87 Tenant, LLC, dated (Filed With SEC on November 10, 2021)
- Employment Agreement, dated as of June 11, 2021, between the Registrant and Andrew Ashe, J.D (Filed With SEC on June 14, 2021)
- Employment Agreement, dated as of June 11, 2021, between the Registrant and Andrew Bellinger, M.D., Ph.D (Filed With SEC on June 14, 2021)
- Employment Agreement, dated as of June 11, 2021, between the Registrant and Sekar Kathiresan, M.D (Filed With SEC on June 14, 2021)
- Summary of Non-Employee Director Compensation Program (Filed With SEC on June 14, 2021)
- Amended and Restated 2021 Employee Stock Purchase Plan (Filed With SEC on June 14, 2021)
- Form of Restricted Stock Unit Agreement under the 2021 Stock Incentive Plan (Filed With SEC on June 14, 2021)
- Form of Stock Option Agreement under the 2021 Stock Incentive Plan (Filed With SEC on June 14, 2021)
- 2021 Stock Incentive Plan (Filed With SEC on June 14, 2021)
- Form of Underwriting Agreement (Filed With SEC on June 14, 2021)
- Second Amended and Restated Investors Rights Agreement, dated as of January 14, 2021, by and among the Registrant and the other parties thereto (Filed With SEC on May 28, 2021)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on May 28, 2021)
- 2018 Equity Incentive Plan (Filed With SEC on May 28, 2021)
- Form of Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on May 28, 2021)
- Collaboration and License Agreement, dated as of April 3, 2019, by and between the Registrant and Beam Therapeutics Inc (Filed With SEC on May 28, 2021)
- Amended and Restated Development and Option Agreement, dated as of October 6, 2020, by and between the Registrant and Acuitas Therapeutics, Inc (Filed With SEC on May 28, 2021)
- Non-Exclusive License Agreement, dated as of October 14, 2020, by and between the Registrant and Acuitas Therapeutics, Inc (Filed With SEC on May 28, 2021)
- Cas9 License Agreement, dated as of March 15, 2019, by and among the Registrant, The President and Fellows of Harvard College and The Broad Institute, Inc., as amended (Filed With SEC on May 28, 2021)
- Sublease, dated as of April 13, 2020, by and between the Registrant and Foghorn Therapeutics Inc., as amended (Filed With SEC on May 28, 2021)
- Offer Letter, dated as of April 16, 2019, by and between the Registrant and Sekar Kathiresan, M.D (Filed With SEC on May 28, 2021)
- Offer Letter, dated as of July 26, 2019, by and between the Registrant and Andrew Ashe, J.D (Filed With SEC on May 28, 2021)
- Offer Letter, dated as of July 26, 2019, by and between the Registrant and Andrew Bellinger, M.D., Ph.D (Filed With SEC on May 28, 2021)
- Form of indemnification agreement between the Registrant and each of its executive officers and directors (Filed With SEC on May 28, 2021)
